COVID-19 vaccine study has a warning for people who take common IBD drug

A new study is alerting people who take a common drug for Irritable Bowel Disease (IBD) that their body’s response to the first COVID-19 vaccine dose may be lower than expected. The issue was observed in people taking an immune-suppressing drug called infliximab, which is commonly prescribed for IBD. Vaccines, including the COVID-19 vaccine, work by triggering the patient’s own …